Lung Cancer Surgery Market Propelled by Robotic-Assisted Minimally Invasive Surgery
Lung cancer surgery involves removal of the part of lung containing cancer cells to treat lung cancer. Key advantages of lung cancer surgery include removal of cancerous tissues to halt the spread of cancer. With rising incidence of lung cancer worldwide, the demand for lung cancer surgery is growing. The global lung cancer surgery Market is estimated to be valued at US$ 6.04 Bn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Robotic-assisted minimally invasive surgery is a key trend propelling the lung cancer surgery market. Minimally invasive surgery uses small incisions instead of traditional open surgery which results in less pain, scarring and recovery time. Robotic systems provide surgeons with enhanced visualization, greater dexterity and precision over keyhole surgery. Growing adoption of robotic surgery in lung cancer is helping to reduce complications and improve patient outcomes which is driving the lung cancer surgery market.
SWOT Analysis
Strength: Lung cancer surgery offers potential cure which increases demand. Minimal invasive procedures reduce recovery time and discomfort for patients.
Weakness: Surgery is highly complex and risky procedure requiring specialized hospitals and staff. Chances of complication and side effects exist even with best available treatment.
Opportunity: Rising incidence of lung cancer worldwide presents growing patient pool. New technologies improving precision and outcomes of surgical removal of tumors.
Threats: Preference for alternative non-surgical treatments and smoke cessation efforts may dampen demand for lung cancer surgery over long run. Economic slowdowns can negatively impact market growth.
Key Takeaways
The Global Lung Cancer Surgery Market Share is expected to witness high growth.
Regional Analysis: The North America region currently dominates the market due to growing incidence of lung cancer, availability of advanced healthcare facilities and favorable reimbursement scenario. The Asia Pacific region is anticipated to grow at fastest pace due to rising healthcare spending, increasing patient awareness and regulatory approvals facilitating adoption of advanced therapies.
Key players operating in the lung cancer surgery are Bunge Limited, Archer Daniels Midland Company, Cargill, Incorporated, Wilmar International Limited, Tyson Foods, Inc.,JBS S.A.,Darling Ingredients Inc.,IOI Corporation Berhad, Ventura Foods, LLC,BRF S.A., Ajinomoto Co., Inc., Premium Vegetable Oils Sdn Bhd, AAK AB, Conagra Brands, Inc., Richardson International Limited. The industry is consolidated with few large players having majority market share. These companies are investing heavily in R&D to develop minimally invasive techniques and robot-assisted surgical approaches to improve recovery time and quality of life for lung cancer patients.
For more details on the report, Read- https://www.ukwebwire.com/lung-cancer-surgery-market-growth-demand-and-overview/
Check below trending articles Related to this topic: https://www.shayaricenter.com/understanding-cancer-biomarkers
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian